Literature DB >> 8293185

The new WHO classification of brain tumours.

P Kleihues1, P C Burger, B W Scheithauer.   

Abstract

The new edition of the World Health Organization (WHO) book on 'Histological Typing of Tumours of the Central Nervous System' reflects the progress in brain tumour classification which has been achieved since publication of the first edition in 1979. Several new tumour entities have been added, including the pleomorphic xanthoastrocytoma, central neurocytoma, the infantile desmoplastic astrocytoma/ganglioglioma, and the dysembryoplastic neuroepithelial tumour. The list of histological variants has also been expanded. In line with recent morphological and molecular data on glioma progression, the glioblastoma is now grouped together with astrocytic tumours. The classification of childhood tumours has been largely retained, the diagnosis primitive neuroectodermal tumour (PNET) only being recommended as a generic term for cerebellar medulloblastomas and neoplasms that are histologically indistinguishable from medulloblastoma but located in the CNS at sites other than the cerebellum. The WHO grading scheme was revised and adapted to new entities but its use, as before, remains optional.

Entities:  

Mesh:

Year:  1993        PMID: 8293185     DOI: 10.1111/j.1750-3639.1993.tb00752.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  324 in total

Review 1.  Brain tumor clinical trials: pitfalls and promise for the future.

Authors:  M R Gilbert
Journal:  Curr Oncol Rep       Date:  2000-11       Impact factor: 5.075

2.  The conditional survival statistics for survivors with primary supratentorial astrocytic tumors.

Authors:  S L Hwang; Y H Yang; A S Lieu; M C Chuang; S J Chang; Y Y Chang; H J Lin; S L Howng
Journal:  J Neurooncol       Date:  2000-12       Impact factor: 4.130

3.  ACP Best Practice No 158. Neuropathology.

Authors:  W R Timperley
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

4.  Comparative genomic hybridization analysis of genetic alterations associated with malignant progression of meningioma.

Authors:  S Ozaki; T Nishizaki; H Ito; K Sasaki
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

5.  Impaired survival and long-term neurological problems in benign meningioma.

Authors:  Hanna van Alkemade; Michelle de Leau; Edith M T Dieleman; Jan W P F Kardaun; Rob van Os; W Peter Vandertop; Wouter R van Furth; Lukas J A Stalpers
Journal:  Neuro Oncol       Date:  2012-03-09       Impact factor: 12.300

6.  A unique model system for tumor progression in GBM comprising two developed human neuro-epithelial cell lines with differential transforming potential and coexpressing neuronal and glial markers.

Authors:  Anjali Shiras; Arti Bhosale; Varsha Shepal; Ravi Shukla; V S Baburao; K Prabhakara; Padma Shastry
Journal:  Neoplasia       Date:  2003 Nov-Dec       Impact factor: 5.715

7.  In vivo correlation of tumor blood volume and permeability with histologic and molecular angiogenic markers in gliomas.

Authors:  R Jain; J Gutierrez; J Narang; L Scarpace; L R Schultz; N Lemke; S C Patel; T Mikkelsen; J P Rock
Journal:  AJNR Am J Neuroradiol       Date:  2010-11-11       Impact factor: 3.825

8.  A global genomic view on LNX siRNA-mediated cell cycle arrest.

Authors:  Dan Zheng; Shaohua Gu; Yao Li; Chaoneng Ji; Yi Xie; Yumin Mao
Journal:  Mol Biol Rep       Date:  2010-11-21       Impact factor: 2.316

9.  Proliferative activity as measured by MIB-1 labeling index and long-term outcome of cerebellar juvenile pilocytic astrocytomas.

Authors:  Karl Roessler; Alexander Bertalanffy; Hussun Jezan; Achmed Ba-Ssalamah; Irene Slavc; Thomas Czech; Herbert Budka
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

10.  Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens.

Authors:  Raymond I Haroun; Richard E Clatterbuck; M Christopher Gibbons; Peter C Burger; Ricardo Parker; John P Fruehauf; Henry Brem
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.